Drugs Referred to the Stakeholder Council
2024 Drugs Referred to the Stakeholder Council
The following drugs were referred to the Stakeholder Council at the March 25, 2025 meeting.
- Biktarvy: 50-200-25 mg
- Dupixent: 300 mg/2mL, 200 mg/1.14mL
- Farxiga: 10 mg, 5 mg
- Jardiance: 25 mg, 10 mg
- Ozempic: 2 mg/1.5mL, 4 mg/3mL, 8 mg/3mL
- Skyrizi
- Skyrizi: 150 mg/mL, 75 mg/0.83mL
- Syrizi Pen: 150 mg/mL
- Trulicity: 0.75 mg/0.5mL,1.5 mg/0.5mL, 3 mg/0.5mL, 4.5 mg/0.5mL
- Vyvanse: 40 mG, 30 mG, 70 mG, 60 mG, 50 mG, 20 mG
View PDF shared to the Stakeholder Council - PDF - 105.66 KB
Opportunities for Public Comment
The comment period for Drugs Referred to the Stakeholder Council began April 10, 2024. Comments were due by COB, Friday, May 10, 2024. Comments may be submitted to [email protected] with “Drugs Referred to the Stakeholder Council Comment" in the subject line.
Drugs Referred to the Stakeholder Council
Comments Received for Drugs Referred to Stakeholder Council
- Boehringer Ingelheim
- Mark Varner
- Chase Brexton (Letter #1)
- AFSCME Maryland
- Maryland Tech Council
- ICER
- ICER- Final Evidence Report- Moderate to Severe Plaque Psoriasis
- ICER- Final Evidence Report- Atopic Dermatitis
- ICER- Final Evidence Report- Treatment of Asthma associated with Type 2 Inflammation
- Chase Brexton (Letter #2)
- AARP Maryland
- Maryland Legislative Coalition
- Mid-Atlantic Association of Community Health Centers
- Gilead
- Community Access National Network
- AbbVie
- Global Coalition on Aging
- National Eczema Association
- Equality Federation
- Chase Brexton (Letter #3)
- HealthHIV
- Richard DeBenedetto, PharmD, MS, AAHIVP
- Sanofi
- Novo Nordisk
- Takeda
- Lilly
The comment period for Therapeutic Alternatives (for Drugs Referred to the Stakeholder Council) began April 10, 2024 for the therapeutic alternatives linked below. Comments were due by COB, Friday, May 10, 2024. Comments may be submitted to [email protected] with “Therapeutic Alternatives" in the subject line.
- Biktarvy Proposed Therapeutic Alternatives
- Farxiga Proposed Therapeutic Alternatives
- Jardiance Proposed Therapeutic Alternatives
- Trulicity Proposed Therapeutic Alternatives
- Ozempic Proposed Therapeutic Alternatives
- Vyvanse Proposed Therapeutic Alternatives
The comment period for Therapeutic Alternatives for Drugs Referred to the Stakeholder Council began April 11, 2024 for the therapeutic alternatives linked below. Comments were due by COB, Monday, May 13, 2024. Comments may be submitted to [email protected] with “Therapeutic Alternatives" in the subject line.
- Dupixent Therapeutic Alternatives
- Skyrizi Therapeutic Alternatives
Comments Received for Therapeutic Alternatives
- Gilead
- Ensuring Access through Collaborative Health
- Dana R. Fasanella, PharmD, CDCES, BCACP
- Boehringer Ingelheim
- PhRMA
- Lilly
- National Eczema Association
- AbbVie
- Sanofi
- AiArthritis
- Dr. Chesahna Kindred
Drugs Referred to the Stakeholder Council- Dashboard (Corrected/Posted 5/15/2024)
This is a sample database that includes non-proprietary data and data that has been approved for public display
Board Selected Drugs
Following the review of the PDASC, the Board selects prescription drug product(s) for cost review.